三生调脂舒联合西药治疗冠脉临界病变（痰瘀互结型）的临床研究

发布时间：2018-12-23 08:01

【摘要】：目的:以冠脉临界病变患者为研究对象,观察三生调脂舒联合西药治疗冠脉临界病变的临床疗效及安全性。方法:选取符合纳入标准的病患78例,随机平均分为两组(对照组、治疗组)。对照组仅用常规西药治疗,治疗组在常规西药治疗基础上加用三生调脂舒治疗,连续治疗12周后判断疗效。结果:1、治疗过程中,三生调脂舒联合西药组及西药组治疗后均未发生一级、二级终点事件;对比治疗前后肝功能(AST、ALT)水平、肾功能(BUN、Cr)的水平,两组药物均未造成指标异常(p0.05),提示三生调脂舒具有一定的安全性。2、治疗后两组冠脉狭窄程度较治疗前无明显变化,提示两组用药可能对延缓冠脉狭窄的发展有一定作用;两组用药后心绞痛症状积分均优于治疗前,有统计学意义;但两组组间比较无显著性差异(p0.05)。3、三生调脂舒联合西药与单纯西药治疗均能降低冠脉临界病变患者中医证候总积分及颈动脉斑块积分,但三生调脂舒联合西药组更具有优势(p0.05);中医证候单项有效情况分析,三生调脂舒联合西药组在改善心悸、气短、痞满、肢体困重、乏力等方面效果较西药组好;但是两组在缓解胸闷、胸痛等方面无明显差异(p0.05)。4、研究结果提示,两组患者治疗后血脂水平较治疗前均有下降,有统计学意义,三生调脂舒联合西药组较西药组优势更明显(p0.05)。结论:三生调脂舒联合西药可明显改善痰瘀互结症状,具有一定安全性,并且在降低颈动脉斑块积分与血脂等方面可产生较好的疗效,但对改善心绞痛症状及缩减冠脉狭窄等方面与单纯使用西药治疗无显著性差异。
[Abstract]:Objective: to observe the clinical efficacy and safety of Sansheng Tiaozhishu combined with western medicine in the treatment of coronary critical disease. Methods: 78 patients who met the inclusion criteria were randomly divided into two groups (control group, treatment group). The control group was treated with routine western medicine, while the treatment group was treated with Sansheng Tiaozhishu on the basis of routine western medicine, and the curative effect was evaluated after 12 weeks of continuous treatment. Results: 1. In the course of treatment, there were no first-grade and second-order terminal events in Sansheng Tiaozhishu combined with western medicine group and western medicine group; Compared with the levels of liver function (AST,ALT) and renal function (BUN,Cr) before and after treatment, the two groups did not cause abnormal indexes (p0. 05), suggesting that Sansheng Tiaozhi Shu was safe to some extent. The degree of coronary stenosis in the two groups did not change significantly after treatment, suggesting that the two groups may have a certain role in delaying the development of coronary artery stenosis. The symptom score of angina pectoris in the two groups was better than that before treatment, which had statistical significance. However, there was no significant difference between the two groups (p0.05). 3. Sansheng Tiaozhishu combined with western medicine and western medicine could reduce the total score of TCM syndromes and carotid plaque score in patients with critical coronary artery disease. But Sansheng Tiaozhishu combined with western medicine had more advantages (p0.05); Analysis of the single effective situation of TCM syndrome, Sansheng Tiaozhishu combined with western medicine group in improving palpitations, shortness of breath, full of ruffiness, limb distress, fatigue and other aspects of the effect is better than the western medicine group; However, there was no significant difference in relieving chest tightness and chest pain between the two groups (p0.05). The results showed that the blood lipid levels in the two groups were significantly lower than those before treatment. The advantage of Sansheng Tiaozhishu combined with western medicine group was more obvious than that of western medicine group (p 0.05). Conclusion: Sanshengtiaozhishu combined with western medicine can obviously improve phlegm and blood stasis syndrome, has certain safety, and can produce better curative effect in reducing carotid plaque score and blood lipid, etc. However, there was no significant difference between the treatment of angina pectoris and the reduction of coronary stenosis.
【学位授予单位】：云南中医学院
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R541.4

【参考文献】